NCT04571697View on ClinicalTrials.gov

A Study of Comparing Rates of Dementia and Alzheimer's Disease in Participants Initiating Methotrexate Versus Those Initiating Anti-tumor Necrosis Factor (TNF)-Alpha Therapy

CompletedOBSERVATIONAL
Enrollment

34,647

Participants

Timeline

Start Date

September 28, 2020

Primary Completion Date

October 27, 2020

Study Completion Date

October 27, 2020

Conditions
DementiaAlzheimer Disease
Interventions
DRUG

Methotrexate

No intervention or treatment will be administered as part of this study. Data of participants with first claim for a methotrexate in the patient's history are included.

DRUG

Anti-TNF

No intervention or treatment will be administered as part of this study. Data of participants with first claim for an anti-TNF in the patient's history are included. Anti-TNF includes infliximab, golimumab, etanercept, certolizumab, and adalimumab.

Trial Locations (1)

08560

Janssen R&D, Titusville

All Listed Sponsors
lead

Janssen Research & Development, LLC

INDUSTRY

NCT04571697 - A Study of Comparing Rates of Dementia and Alzheimer's Disease in Participants Initiating Methotrexate Versus Those Initiating Anti-tumor Necrosis Factor (TNF)-Alpha Therapy | Biotech Hunter | Biotech Hunter